AstraZeneca (Wilmington, Del) recently received FDA approval for Nexium IV for injection. The product is indicated for intravenous (IV) infusion or injection for the short-term treatment (up to 10 days) of gastroesophageal reflux disease in patients with a history of erosive esophagitis who are unable to take capsules. The recommended adult dosage regimen for the product is either 20 or 40 mg of Nexium IV given once daily by IV injection (=3 minutes) or IV infusion (10 to 30 minutes). Nexium IV is supplied as a freeze-dried powder containing 20 or 40 mg of esomeprazole per single-use vial. For more information, visit www.nexium-us.com, or call 800-237-8898.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs